Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

We recently reported that a sequence variant in the cell-cycle-checkpoint kinase CHEK2 (CHEK2 1100delC) is a low-penetrance breast cancer-susceptibility allele in noncarriers of BRCA1 or BRCA2 mutations. To investigate whether other CHEK2 variants confer susceptibility to breast cancer, we screened the full CHEK2 coding sequence in BRCA1/2-negative breast cancer cases from 89 pedigrees with three or more cases of breast cancer. We identified one novel germline variant, R117G, in two separate families. To evaluate the possible association of R117G and two germline variants reported elsewhere, R145W and I157T with breast cancer, we screened 737 BRCA1/2-negative familial breast cancer cases from 605 families, 459 BRCA1/2-positive cases from 335 families, and 723 controls from the United Kingdom, the Netherlands, and North America. All three variants were rare in all groups, and none occurred at significantly elevated frequency in familial breast cancer cases compared with controls. These results indicate that 1100delC may be the only CHEK2 allele that makes an appreciable contribution to breast cancer susceptibility.

[1]  D. Stern,et al.  Chk2 Activation and Phosphorylation-Dependent Oligomerization , 2002, Molecular and Cellular Biology.

[2]  Michael B Yaffe,et al.  Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. , 2002, Molecular cell.

[3]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[4]  R. Eeles,et al.  A robust method for detecting CHK2/RAD53 mutations in genomic DNA , 2002, Human mutation.

[5]  Jing Chen,et al.  Characterization of Tumor-associated Chk2 Mutations* , 2001, The Journal of Biological Chemistry.

[6]  N. Mailand,et al.  The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.

[7]  J. Bartek,et al.  Chk2 kinase — a busy messenger , 2001, Nature Reviews Molecular Cell Biology.

[8]  L. Aaltonen,et al.  p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. , 2001, Cancer research.

[9]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[10]  Peter Devilee,et al.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.

[11]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[12]  S. Elledge,et al.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Durocher,et al.  The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. , 2000, Molecular cell.

[14]  R. Winqvist,et al.  Mutation analysis of the CHK2 gene in families with hereditary breast cancer , 2001, British Journal of Cancer.

[15]  B. Gusterson,et al.  Analysis of CHK2 in vulval neoplasia , 2002, British Journal of Cancer.

[16]  O. Delattre,et al.  Detection of 11 germline inactivating TP53 mutations and absence of TP63 andHCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome , 2001, Journal of medical genetics.

[17]  D J Prockop,et al.  Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[19]  B. Gusterson,et al.  Concomitant inactivation of p53 and Chk2 in breast cancer , 2002, Oncogene.

[20]  R. Barkardottir,et al.  Mutation analysis of the CHK2 gene in breast carcinoma and other cancers , 2001, Breast Cancer Research.

[21]  W. Hofmann,et al.  Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. , 2001, Leukemia research.

[22]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[23]  C. O. Parker,et al.  The North Cumbria Community Genetics Project. , 1998, Journal of medical genetics.

[24]  S. Moreno,et al.  Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1 , 1998, Nature.

[25]  Jong-Soo Lee,et al.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.

[26]  D. Sgroi,et al.  Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. , 2001, Cancer research.

[27]  S. Elledge,et al.  Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.

[28]  H.-H. Essen,et al.  Microseismological evidence for a changing wave climate in the northeast Atlantic Ocean , 2000, Nature.